November 9, 2023 | Genomics
Top 3 considerations for targeted sequencing of myeloid neoplasms
Unraveling the mutational landscape of myeloid neoplasms with targeted NGS
Myeloid neoplasms are a group of diseases characterized by abnormal growth of bone marrow cells. These disorders involve a myriad of mutations in multiple genes, including oncogenes and tumor suppressor genes. Targeted DNA sequencing has emerged as a game-changer when it comes to studying myeloid neoplasms. It allows the identification of variants responsible for these conditions, providing a comprehensive mutational profile of myeloid neoplasms. These insights pave the way for biomarker and drug discovery.
However, to maximize the potential of targeted NGS, you need an efficient, standardized and straightforward workflow that doesn’t drain resources. You also need to be able to detect low variant allele frequencies with confidence. How can you be certain you haven’t missed an important variant? How can you capture the complexity of these disorders? How long is it going to take? If you’re confronted with these questions, we have a checklist that can help narrow down the most important criteria when it comes to choosing targeted NGS panels for myeloid neoplasms.
Let’s delve into why the following three factors are pivotal in enhancing the effectiveness of targeted DNA sequencing for detecting variants in myeloid neoplasms.
1. Turnaround time: Accelerate disease insights
In the context of myeloid neoplasms, time is of the essence. Traditional sequencing methods are time-consuming and could take weeks, even months, to produce results.
However, the emergence of high-throughput sequencing technologies has drastically lowered time scales. Targeted DNA sequencing, with its ability to analyze multiple genes in a single test, significantly reduces the time needed for comprehensive mutation profiles.
However, not all targeted NGS panels are created equal. Some have exceptionally long turnaround times. This can mean an inefficient use of laboratory resources and unnecessary delays in getting results and disease insights.
2. Automation: Enhancing accuracy and scalability
The complexity of genetic analysis, especially in the context of myeloid neoplasms, demands a high degree of precision and consistency. Manual handling of samples and data analysis is time-consuming and susceptible to human error. Automation streamlines the sequencing process, minimizing human intervention and enhancing the reliability of results. Best of all, automation reduces the chances of sample contamination and cross-contamination, ensuring the integrity of results.
Automated workflows boost productivity and allow researchers and clinicians to analyze a larger volume of samples simultaneously, improving efficiency and reducing the overall turnaround time. This scalability is particularly significant when studying myeloid neoplasms, as these disorders often require continuous monitoring over time. The ability to handle a high volume of samples efficiently ensures that researchers have access to the most up-to-date and comprehensive genetic information.
3. Ease of use: Democratizing DNA sequencing
Simplifying the process of targeted DNA sequencing promotes the democratization of genetic testing for myeloid neoplasms. The power of advanced sequencing techniques shouldn't be confined to a handful of experts. Ensuring that the technology is user-friendly and accessible is vital for widespread adoption, both in research and clinical settings. Streamlining the steps involved in library preparation, data analysis and interpretation of results allows scientists and clinicians with varying levels of expertise to harness the potential of targeted DNA sequencing.
Easy-to-use protocols encourage interdisciplinary collaboration. Geneticists, hematologists, oncologists and bioinformaticians can collaborate seamlessly, bringing their diverse expertise to the table for comprehensive genomic profiling and novel research insights.
Combining all three
The convergence of faster turnaround time, automation and ease of use has the potential to significantly improve your ability to efficiently investigate myeloid neoplasms using NGS. As we continue to unravel the genetic underpinnings of these complex disorders, these factors have become indispensable in driving research advancements. By exploiting the power of technology, oncology researchers are moving closer to a future where timely, accurate and tailored treatments transform the landscape of myeloid neoplasm management.
Explore the QIAseq advantage
Our QIAseq Targeted DNA Pro Panels have been developed with these stringent criteria in mind. They provide a fast, automation-friendly, straightforward workflow to optimize myeloid disorder insights. You can go from sample to sequencing-ready libraries in less than 6 hours with just 2 hours of hands-on time. This means that QIAseq Targeted DNA Pro Panels are the fastest solution for detecting low variant allele frequencies with high confidence. The reduced viscosity of reagents, simplified workflow and elimination of time-consuming bead cleanups make the panels particularly amenable to automation. Interested in learning more about QIAseq Targeted DNA Pro Panels for myeloid neoplasm detection? Take a look here.